Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

NCT03258008 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03258008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03258008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
April 4, 2018
Completion date
November 5, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasms of ill-defined secondary and unspecified sites, malignant neoplasms of lip oral cavity and pharynx, oropharyngeal cancer